Synaptogenix, Inc.

4.86 USD
+0.11 (+2.32%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Synaptogenix, Inc. stock is up 12.24% since 30 days ago. The next earnings date is May 31, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 May’s closed higher than April.

About Synaptogenix, Inc.

Synaptogenix, Inc. focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.